Research Paper

Variants of FasL and ABCC5 are predictive of outcome after chemotherapy-based treatment in osteosarcoma

Xu Leilei¹, Xia Chao¹, Sun Qi², Sheng Fei¹, Xiong Jin¹, Wang Shoufeng¹*,

¹ Department of Orthopedic Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Zhongshan Road 321, Nanjing 210008, China
² Department of Pathology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, China

ARTICLE INFO

Keywords:
Pharmacogenetics
Osteosarcoma
Variants
FASL
ABCC5

ABSTRACT

Objectives: Previous pharmacogenetics studies showed that genetic variants could be indicative of the response to chemotherapy. We aimed to investigate whether variants of FasL, MSH2, ABCC5, CASP3 and CYP3A4 are associated with the outcome after chemotherapy-based treatment in osteosarcoma.

Methods: 132 osteosarcoma patients who had completed the neoadjuvant chemotherapy in our center were included. 5-year progression-free survival (PFS) was assessed from the initial treatment to the earliest sign of disease progression or death from any cause. 5 SNPs were genotyped using TaqMan SNP Genotyping Assay, including rs763110 of FasL, rs4638843 of MSH2, rs939338 of ABCC5, rs2720376 of CASP3 and rs4646437 of CYP3A4. Patients were classified into two groups according to the 5-year PFS (event/no event). The chi-square test was used to analyze difference of genotype frequency. Logistic regression analysis was used to determine the independent predictors of the PFS rate.

Results: The overall 5-year PFS was 61.4% (81/132). Genotype TT/CT of rs763110 and genotype GG/AG of rs939338 were significantly associated with the event of 5-year PFS \( p = 0.028 \) for rs763110; \( p = 0.039 \) for rs939338. Patients with no risk allele showed a 5-year PFS of 73.7% (42/57), which was significantly higher than a PFS of 54.2% (26/48) for patients with one risk allele and 48.1% (13/27) for patients with two different risk alleles \( p = 0.03 \). Logistic regression analysis showed that allele T of FasL rs763110 and allele G of ABCC5 rs939338 were independent risk factors of the 5-year PFS. The ORs were 2.14 (95%CI = 1.13–3.35, \( p = 0.01 \)) for rs763110 and 1.73 (95%CI = 1.05–2.52, \( p = 0.03 \)) for rs939338, respectively.

Conclusions: The association of variants of FASL and ABCC5 with survival outcome after chemotherapy was validated in patients with osteosarcoma. Our findings may provide a new insight into a more personalized treatment for patients with osteosarcoma.

1. Introduction

Osteosarcoma is a common primary malignant bone tumor predominantly located in the metaphyses of the distal femur, proximal tibia and proximal humerus [1]. Since its advent in 1970s, neoadjuvant chemotherapy has greatly promoted the survival rate of osteosarcoma patients [2,3]. The backbone drugs currently used in neoadjuvant chemotherapy of osteosarcoma included doxorubicin, cisplatin, methotrexate and ifosfamide [4]. Despite the reported effectiveness of these chemotherapeutics, patients were found to have highly varied sensitivity to these agents regarding the antitumor effect and the toxic side-effect [5]. To date, few predictors have been reported to be indicative of the overall survival after the completion of neoadjuvant chemotherapy [6–8]. Reliable predictive factors awaits to be uncovered to identify patients who may benefit less from the chemotherapy.

Pharmacogenetics of cancer treatment mainly refers to the inherited variability of drug response [9]. In previous studies, candidate gene analysis and pathways-based gene analysis were employed to explore pharmacogenetic markers [5]. To date, a few genetic polymorphisms have been found predictive of sensitivity and toxicity of chemotherapy in osteosarcoma through candidate gene analysis. Polymorphisms of ERCC1 were reported to play important roles in the response to cisplatin mediated by the DNA repair pathway [10]. MTHFR C677T polymorphism was identified as a predictor of MTX toxicity in osteosarcoma patients [11]. The SNPs of ABCB1 and ABCC3 were found significantly associated with pharmacokinetic parameters and the occurrence of MTX toxicity [12,13]. To facilitate risk stratification and personalized treatment, establishment of a prediction model based on these genetic variants are warranted.

In a recent study, Hagleitner et al. [14] investigated genes variations

* Corresponding author.
E-mail addresses: wangshoufeng@nju.edu.cn, wsf0135_drumtower@126.com (S. Wang).
involved in the metabolism of cisplatin and doxorubicin in 126 patients with osteosarcoma. Five variants in Fasl, MSH2, ABCCS, CASP3 and CYP3A4 were combined in a risk prediction model to differentiate patients with different progression-free survival (PFS) [14]. The authors reported a PFS of 100% in patients with none or only one risk allele [14]. Since there exists remarkable genomic heterogeneity in osteosarcoma, replication of these five SNPs in additional cohorts of patients is warranted to confirm the efficacy of the predictive model. In the current study, we investigated the association of five variants of Fasl, MSH2, ABCCS, CASP3 and CYP3A4 with the 5-year PFS in a cohort of osteosarcoma patients who had completed the neoadjuvant chemotherapy. Moreover, we analyzed the functional role of these variants in the gene expression.

2. Methods

2.1. Subjects

This study was approved by the ethics committee of our University Medical Center. 132 osteosarcoma patients who had completed the neoadjuvant chemotherapy in our center were included. Informed consent was obtained from all patients or their guardians. All the patients underwent the same chemotherapy regimens consisted of cisplatin (300 mg/m²), doxorubicin (80 mg/m²) and methotrexate (10 g/m²) with a minimum of 5-year follow-up. Clinical data were collected from the medical record retrospectively. PFS was assessed from the initial treatment to the earliest sign of disease progression or death from any cause. Good response to the treatment was defined as with <10% vital cells after two cycles of preoperative chemotherapy therapy [15].

2.2. Genotyping of target variants

The peripheral blood was collected from each patient at the initial visit. DNA was then extracted using the DNA extraction kit (QIAGEN, Tokyo, Japan) according to the protocol of the manufacturers. 5 SNPs were genotyped using TaqMan SNP Genotyping Assay, including rs763110 of Fasl, rs4638843 of MSH2, rs939338 of ABCCS, rs2720376 of CASP3 and rs4646437 of CYP3A4 [14]. The genotyping assay was performed with ABI 7900HT Sequence Detection System (Applied Biosystems, Foster City, CA). Ten percent of the samples were randomly selected to validate the genotyping results. The reproducible rate was 100%.

2.3. Expression analysis in tumor samples

The tumor samples were collected from 56 patients during the resection surgery and stored at −80 °C. The total RNA was extracted from the tumor tissue using the TaKaRa MiniBEST Universal RNA Extraction Kit (TaKaRa, Tokyo, Japan). Real-time PCR was carried out to quantify the mRNA expression level for above-mentioned 5 genes on the ABI 7900HT Detection System (Applied Biosystems, Foster City, CA). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the endogenous control gene. The specific primers of the target genes were listed in Table 1. All amplification procedures were repeated in triplicate, with a mean value of threshold cycle (Ct) scores used to calculate the expression level with ΔΔCt method.

2.4. Statistical analyses

The Hardy–Weinberg equilibrium (HWE) test was performed to exclude selection bias. Patients were classified into two groups according to the 5-year PFS (event/no event). For the inter-group comparison, the Chi-square test was used to analyze difference of genotype frequency and the Student’s t test was used to analyze the difference of gene expression level. Specifically, a dominant model was used to compare the association between genotype and PFS. The odds ratios (OR) and 95% confidence interval (95% CI) were calculated with the risk allele as reference. In addition, the student t test was used to compare the gene expression level between patients with risk allele and those without risk-allele. Logistic regression analysis was used to determine the independent predictors of the PFS rate. Genotype was coded as 0 for homozygotes of non-risk allele and 1 for heterozygotes and homozygotes of risk allele. Response to preoperative chemotherapy treatment was coded as 0 for good response and 1 for bad response. According to different number of the risk alleles, the 5-year PFS curves were analyzed using the Kaplan–Meier method. All the statistical analyses were performed with the SPSS software (version 17.0, Chicago, IL). Statistical significance was set at p < 0.05.

3. Results

3.1. Demographic data of the patients

The mean age of patients was 35.2 ± 19.8 years old. 74 patients (56.1%) had tumor metastasis at the initial visit. 102 (77.3%) patients received limb salvage surgery. 49 (37.1%) patients showed good response to chemotherapy. The overall 5-year PFS was 61.4% (81/132). By the end of the 5-year follow-up, 42 (31.8%) patients had died for tumor recurrence or metastasis.

3.2. Genetic association with 5-year PFS

The genotyping results of the 5 SNPs were listed in Table 2. Genotype TT/CT of rs763110 and genotype GG/AG of rs939338 were significantly associated with the event of 5-year PFS (p = 0.028 for rs763110; p = 0.039 for rs939338). The frequency of genotype CC of rs4638843 was 1. As for rs2720376 and rs4646437, no significant association with 5-year PFS was found. Patients with no risk allele showed a 5-year PFS of 73.7% (42/57), which was significantly higher than a PFS of 54.2% (26/48) for patients with one risk allele and 48.1% (13/27) for patients with two different risk alleles (p = 0.03, Fig. 1).

3.3. Logistic regression analysis of risk factors

Logistic regression analysis showed that allele T of Fasl rs763110 and allele G of ABCCS rs939338 were independent risk factors of the 5-year PFS. The ORs were 2.14 (95%CI = 1.13–3.35, p = 0.01) for rs763110 and 1.73 (95%CI = 1.05–2.52, p = 0.03) for rs939338, respectively. With the cut-off value set as 0.5, the sensitivity and

---

Table 1: Primers for the qPCR assay.

| Gene     | Forward primer | Reverse primer |
|----------|----------------|---------------|
| Fasl     | TGGCTGTGATTTGGTGTGGC | GCTGTTGAGCTCCTGGAAGTTC |
| ABCCS    | TGGTTTGTCGAGGGCTCA    | AGTGGCAGCCTTCCTCCCTCA |
| MSH2     | AGCTGACGGAGGAGGATTTG    | GGATTGCAATCCTGACCTCA |
| CASP3    | CAGTGCAACGGGATTTGGCTC   | CTGGTTTTTGAATCTTGTCG |
| CYP3A4   | ATGGGCTTTATGCCTAACTG    | GCTGTTGAGCTCCTGGAAGTTC |
| GAPDH    | GAGTCAACGGGATTTGGTGGT    | TTGATTGGAGGATCTCCTG |

---
Table 2
Association of the four SNPs with 5-year PFS.

| SNPs            | Genotype\(^c\) | Allele type | \(p\) | Odds ratio (95%CI)\(^d\) |
|-----------------|----------------|-------------|-------|-------------------------|
|                 | Event (n = 51) | No event (n = 81) |       |                         |
| rs763110 (T/C)  | 27/24          | 26/55       |       |                         |
| rs939338 (G/A)  | 25/26          | 24/57       |       |                         |
| rs2720376 (T/C) | 19/32          | 28/53       |       |                         |
| rs4646437 (A/G) | 11/40          | 23/58       |       |                         |

\(^a\) The two values in the ‘genotype’ column indicate the number of homozygotes with respect to the mutant allele plus heterozygotes and the number of homozygotes with respect to the wildtype allele, respectively. i.e. for rs763110, the two values indicate the number of genotype TT + TC and the number of genotype CC, respectively.

\(^b\) Calculated for the alleles.

![Graph](image)

**Fig. 1.** Five-year PFS based on number of risk allele.

Patients with no risk allele showed a 5-year PFS of 81.4%, which was significantly higher than a PFS of 55.0% for patients with one risk allele and 44.8% for patients with two different risk alleles (\(p = 0.003\)).

Specificity of the regression model was 81.5% and 63.3%, respectively. No significant association was found between 5-year PFS and other factors including rs4646437 of CYP3A4, rs2720376 of CASP3 and response to the chemotherapy.

3.4. Relationship between gene expression and 5-year PFS

Of the 56 patients, 4 patients were excluded from the expression analysis due to the degradation of the tissue. As shown in **Table 3**, patients with no event of PFS were found to have significantly higher expression of FasL and lower expression of ABCC5 than those with event of PFS (0.00022 ± 0.00013 vs. 0.00009 ± 0.000023, \(p = 0.03\)). Patients with genotype GG/GA of rs939338 were found to have remarkably higher expression of ABCC5 than those with genotype AA (0.0051 ± 0.0032 vs. 0.0088 ± 0.0049, \(p = 0.001\)) (Fig. 2).

### Table 3
Association of gene expression with 5-year PFS.

| Gene expression | 5-year PFS | \(p\) |
|-----------------|------------|-------|
|                 | Event (n = 23) | No event (n = 29) |       |
| Fasl            | 0.00025 ± 0.00014 | 0.00037 ± 0.00021 | 0.02 |
| ABCC5           | 0.00084 ± 0.00041 | 0.00058 ± 0.00027 | 0.008 |
| MSH2            | 0.00042 ± 0.00027 | 0.00053 ± 0.00031 | 0.18 |
| CASP3           | 0.00073 ± 0.00036 | 0.00065 ± 0.00029 | 0.37 |
| CYP3A4          | 0.00085 ± 0.00041 | 0.00093 ± 0.00052 | 0.55 |

4. Discussion

Neoadjuvant treatment including cisplatin with doxorubicin, methotrexate, and ifosfamide has been frequently used for osteosarcoma [16–18]. However, differential outcome was observed among patients receiving even the same therapeutic protocol. In previous studies, genetic polymorphisms have been shown to indicate patients’ response to chemotherapeutic agents which eventually could influence the final survival [10–13]. Herein, integration of such predictive genetic markers is crucial to optimize risk stratification and personalize chemotherapy strategy. For patients who are predicted to respond poorly to the standardized treatment, alternative or more aggressive therapies could be offered to them for a better outcome.

In this study, we validated a previously reported predictive model that was significantly associated with 5-year PFS of osteosarcoma. Among the 5 variants encompassed in the model, rs763110 and rs939338 were successfully replicated in our cohort of patients. We confirmed that both allele T of rs76310 and allele G of rs939338 were risk factors of decreased 5-year PFS. Based on these two variants, our predictive model can produce a sensitivity of 81.5% and a specificity of 63.3%, respectively. As for the other 3 SNPs, no significant association with the 5-year PFS was found. Specifically, there was no mutant allele of rs4638843 in our cohort. Obviously, the ethnic differences between the Chinese population and the White population could yield great divergence regarding the predictive power of genetic markers. In the study of Hagleitner et al. [14], patients with 5 or more risk alleles can have a 5-year PFS of 41.8%, which was remarkably lower than a 5-year PFS of 100% in patients with no risk allele. Comparably, we observed that patients with allele T of rs763110 and allele G of rs939338 had obviously lower 5-year PFS than those with less than 2 risk alleles. Although having less predictive power as indicated in the current study, the previously reported model was preliminarily validated in our cohort of patients. More causative variants need to be included to increase the reliability of the model.

Identification of the informative gene is critically important for understanding the biological basis of the association between the variants and the clinical outcome. The two informative genes identified in this study were Fasl and ABCC5. In previous study, upregulation of the Fas/Fasl has been observed in the apoptosis of tumor cells after treatment with chemotherapeutic drugs such as cisplatin [19]. The Fas/Fasl system was found almost inactive in cisplatin-resistant cell lines [20]. Moreover, Gordon and Kleinerman [21] reported that Fasl...
expression was inversely correlated with metastatic events of osteosarcoma. In addition to FAS/FASL, previous experiments also showed that higher expression of ABC5 is associated with the resistance to cisplatin and doxorubicin in different cancer cell lines. In this study, through expression analysis, we found for the first time that the Fasl and ABC5 expression were remarkably correlated with 5-year PFS of osteosarcoma patients. In the luciferase reporter assays reported by Wu et al., allele T of rs763110 was associated with a decreased promoter activity of FASL. The eQTL dataset showed that allele G of rs939338 was linked to a higher expression of ABC5. In line with these findings, we confirmed that patients with genotype TT/TC of rs763110 had remarkably lower expression of Fasl than those with genotype CC. Moreover, patients with genotype GG/GA of rs939338 were found to have remarkably higher ABC5 expression than those with genotype AA. Taken together, patients carrying these two risk alleles may benefit less from cisplatin and doxorubicin, which could be taken into account to guide a personalized chemotherapy.

Two limitation of our study should be addressed. As osteosarcoma is a rare disease, the number of patients included in our study is relatively small for a genetic association study. A multi-center study that recruits more patients is warranted to overcome the limitation resulted from the small sample size. The second limitation lies in a paucity of in vitro experiments investigating the influence of the mutant on the cancer cell viability treated by cisplatin or doxorubicin. Future functional studies will provide more clues underlying the relationship between the reported variants and resistance to the chemotherapy drugs.

In summary, the association of FASL and ABC5 with survival outcome after chemotherapy was validated through a replication study in our cohorts. Moreover, we additionally demonstrated that the expression levels of the identified genes could be indicative of the final outcome. These findings may provide a new insight into a more personalized treatment for patients with osteosarcoma.

Acknowledgment

This work was supported by the National Natural Science Foundation of China (Grant Nos. 81501849 and 81201385) and by the Nanjing Key Program of Medical Science and Technology Development (Grant No. ZKX14021).

Conflict of interest

No benefits in any form have been or will be received from a commercial party related directly or indirectly to the subject of this manuscript.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.jbo.2018.04.003.

References

[1] A.H. Aljubran, A. Griffin, M. Pinillie, et al., Osteosarcoma in adolescents and adults: survival analysis with and without lung metastases, Ann. Oncol. Off. J. Eur. Soc. Med. Oncol./ESMO 29 (2009) 1136-1141.
[2] G. Yuan, J. Chen, D. Wu, et al., Neoadjuvant chemotherapy combined with limb salvage surgery in patients with limb osteosarcoma of Enneking stage II: a retrospective study, Oncol. Targets Ther. 10 (2017) 2745-2750.
[3] G. Bacci, A. Longhi, M. Vernari, et al., Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution, Cancer 106 (2008) 1154-1161.
[4] Group ESESNW, Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann. Oncol. Off. J. Eur. Soc. Med. Oncol./ESMO 25 (Suppl 3) (2014) iii113-23.
[5] H.I. Ves, M.J. Coenen, H.J. Guchelaar, et al., The role of pharmacogenetics in the treatment of osteosarcoma, Drug Discov. Today 21 (2016) 1775-1786.
[6] Y. Li, T.A. Dang, J. Shen, et al., Plasma proteome predicts chemotherapy response in osteosarcoma patients, Oncol. Rep. 25 (2011) 303-314.
[7] J.W. Martin, S. Chilton-MacNeil, M. Keti, et al., Digital expression profiling identifies RUNX2, CDC5L, MDM2, REQL4, and CDK4 as potential predictive biomarkers for neo-adjuvant chemotherapy response in paediatric osteosarcoma, PloS One 9 (2014) e95843.
[8] G. Bacci, S. Ferrari, M. Mercuri, et al., Predictive factors for local recurrence in osteosarcoma: 540 patients with extremism tumors followed for minimum 2.5 years after neoadjuvant chemotherapy, Acta Orthop. Scand. 69 (1998) 230-236.
[9] C.D. Hartinger, M. Serra, Role of pharmacogenetics of drug-metabolizing enzymes in treating osteosarcoma, Exp. Opin. Drug Metabol. Toxicol. 11 (2015) 1449-1463.
[10] Q. Zhang, L.Y. Lv, B.J. Li, et al., Investigation of ERCC1 and ERCC2 gene polymorphisms and response to chemotherapy and overall survival in osteosarcoma, Genet. Mol. Res. 14 (2015) 11235-11241.
[11] L. Lambrecht, C. Steurs, V. Labarque, et al., The role of the MTHFR C677T polymorphism in methotrexate-induced toxicity in pediatric osteosarcoma patients, Pharmacogenomics 18 (2017) 787-795.
[12] J.W. Kim, H.Y. Yun, B. Choi, et al., ABCB1 C3435T genetic polymorphism on population pharmacokinetics of methotrexate after hematopoietic stem cell transplantation in Korean patients: a prospective analysis, Clin. Ther. 34 (2012) 1816-1826.
[13] M.C. de Rotte, M. Bulatovic, M.W. Heijstek, et al., ABCB1 and ABCC3 gene polymorphisms are associated with first-year response to methotrexate in juvenile idiopathic arthritis, J. Rheumatol. 39 (2012) 2032-2040.
[14] M.M. Haglindner, M.J. Coenen, H. Gelderblom, et al., A first step toward personalized medicine in osteosarcoma: pharmacogenetics as predictive marker of outcome after chemotherapy-based treatment, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 21 (2015) 3436-3441.
[15] Z. Bagel-Horvath, K. Schmid, F. Rossler, et al., Import of RANK-signalling on survival and chemotherapy response in osteosarcoma, Pathology 46 (2014) 411-415.
[16] G. Bacci, M. Rocca, M. Salone, et al., High grade osteosarcoma of the extremities with lung metastases at presentation: treatment with neoadjuvant chemotherapy and simultaneous resection of primary and metastatic lesions, J. Surg. Oncol. 98 (2008) 415-420.
[17] G. Bacci, A. Briccoli, A. Longhi, et al., Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy, Acta Oncol. 44 (2005) 748-755.
[18] G. Bacci, C. Forni, S. Ferrari, et al., Neoadjuvant chemotherapy for osteosarcoma of the extremity: intensification of preoperative treatment does not increase the rate of...
good histologic response to the primary tumor or improve the final outcome, J. Pediatr. Hematol/Oncol. 25 (2003) 845–853.
[19] R. Koster, H. Timmer-Bosscha, R. Bischoff, et al., Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway, Cell Death Dis. 2 (2011) e148.
[20] D.C. Spierings, E.G. de Vries, E. Vellenga, et al., Loss of drug-induced activation of the CD95 apoptotic pathway in a cisplatin-resistant testicular germ cell tumor cell line, Cell Death Differ. 10 (2003) 808–822.
[21] N. Gordon, E.S. Kleinerman, The role of Fas/FasL in the metastatic potential of osteosarcoma and targeting this pathway for the treatment of osteosarcoma lung metastases, Cancer Treat. Res. 152 (2009) 497–508.
[22] S. Pratt, R.L. Shepard, R.A. Kandasamy, et al., The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites, Mol. Cancer Ther. 4 (2005) 855–863.
[23] J. Wu, C. Metz, X. Xu, et al., A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients, J. Immunol. 170 (2003) 132–138.
[24] H.J. Westra, M.J. Peters, T. Esko, et al., Systematic identification of trans eQTLs as putative drivers of known disease associations, Nat. Genet. 45 (2013) 1238–1243.